AbbVie Reports Exploratory P-II (NOVA) Trial Results of AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
Shots:
- The exploratory P-II (NOVA) dose-ranging study evaluates AGN-151607 in patients with POAF undergoing open-chest cardiac surgery
- The 1EPs were not met for evaluating the occurrence of continuous AF ≥30 seconds for the mITT population, relative risk reduction was observed in specific study populations i.e., CABG patients and in patients aged ≥65yrs. with 29% relative risk reduction over PBO
- In a post hoc analysis, patients treated with 125 units of AGN-151607 showed a 51% greater risk reduction with lower rates of all-cause re-hospitalization within 30 days over PBO (8.7% vs 15.7%) while 62.9% vs 45.1% were atrial fibrillation-free and anticoagulation-free, treatment discontinuation due to AE and rates of AEs were numerically similar across the three treatment groups
Ref: AbbVie | Image: AbbVie
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
